Prevalence of multiple sclerosis in Poland

Kapica-Topczewska, Katarzyna; Brola, Waldemar; Fudala, Małgorzata; Tarasiuk, Joanna; Chorąży, Monika; Snarska, Katarzyna; Kochanowicz, Jan; Kułakowska, Alina

doi:10.1016/j.msard.2018.02.016

Cited by 37 publications

(35 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study is the first one to have enrolled all RRMS patients treated with DMTs reimbursed by the NFZ in Poland. The mean age of participants and the sex ratio are similar to previously reported observations from Poland and other countries [1][2][3][4][5][6][7][8][9][10]. Interestingly, we found that a significantly higher percentage of men was treated in the second-line programme than in the first-line.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland

Kapica-Topczewska

Collin

Tarasiuk

et al. 2020

Neurol Neurochir Pol.

Self Cite

View full text Add to dashboard Cite

Aim of study. The aim of this study was to collect and analyse data on relapsing-remitting multiple sclerosis (RRMS) patients receiving disease-modifying therapies (DMTs) in Poland. Material and methods. This observational, multicentre study with prospective data collection included RRMS patients receiving DMTs reimbursed by the National Health Fund (NFZ) in Poland, monitored by the Therapeutic Programme Monitoring System (SMPT). Demographic profiles, disability status, and treatment modalities were analysed. Results. Data from 11,632 RRMS patients (from 15,368 new prescriptions) was collected including 10,649 patients in the first-line and 983 in the second-line therapeutic programme of DMTs. The proportion of females to males was 2.39 in the first-line and 1.91 in the second-line. The mean age at DMTs start was 36.6 years in the first-line and 35.1 in the second-line. The median time from the first symptoms to MS diagnosis was 7.4 months, and from MS diagnosis to treatment it was 18.48 months. A total of 43.4% of MS patients started DMT during the 12 months following diagnosis. There was a positive correlation between the duration from MS diagnosis to the start of DMT and a higher initial EDSS value [correlation 0.296 (p < 0.001)]. About 10% of patients stopped DMTs. In Poland, about one third of all MS patients are treated in both lines of therapeutic programmes, and the choice of first-line treatment depends on the region of the country. Conclusions. In Poland there is a need to increase MS patient access to DMTs by improving the organisation of therapeutic programmes.

show abstract

Section: Discussionsupporting

confidence: 89%

“…The estimated number of people suffering from MS worldwide is approximately 2.3 million [1,2]. In Poland, there are around 45,000 patients, with a prevalence of approximately 110-115/100,000 residents [3,4].…”

Section: Introductionmentioning

confidence: 99%

Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland

Kapica-Topczewska

Collin

Tarasiuk

et al. 2020

Neurol Neurochir Pol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…23 A recent study has shown that Poland is a high-risk area for MS, with the overall crude prevalence rate of confirmed MS patients approximately 110/100 000 inhabitants. 24 As the current population of Poland is almost 38.5 million people, this prevalence of MS equates to approximately 42 000 patients. In SCI, it has been estimated that approximately 81% of SCI patients will undergo some degree of urinary dysfunction within 1 year, and <1% of these patients will make a full recovery.…”

Section: Discussionmentioning

confidence: 99%

Neurogenic bladder symptom score: Polish translation, adaptation and validation of urinary disorder‐specific instrument for patients with neurogenic lower urinary tract dysfunction

Przydacz

Dudek

Gołąbek

et al. 2020

Int. J. Clin. Pract.

View full text Add to dashboard Cite

Introduction There is no comprehensive and specific questionnaire translated, adapted and validated in the Polish language for evaluating symptoms, quality of life and complications associated with the neurogenic lower urinary tract dysfunction (NLUTD). The aim of this study was to translate, culturally adapt and validate a Polish version of the Neurogenic Bladder Symptom Score (NBSS) for patients who experience NLUTD. Material and Methods Standardised guidelines and well‐established methods were used for translation and cross‐cultural adaptation of the NBSS. Adult patients with multiple sclerosis and spinal cord injury completed the NBSS, the International Consultation on Incontinence Questionnaire‐Short Form (ICIQ‐SF), the International Prostate Symptom Score (IPSS) and the SF‐Qualiveen. Responses were recorded twice within a 14‐day period. Results Two hundred seventy‐four Polish‐speaking patients with NLUTD were included in the study. Content validity was optimal. Significant relationships between NBSS (Incontinence) and ICIQ‐SF, NBSS (Storage and Voiding) and IPSS, and NBSS (Quality of Life) and SF‐Qualiveen confirmed good construct/criterion validity. An intercorrelation study revealed that internal consistency was good for the total NBSS and specific domains (Cronbach's alpha >0.7). Test‐retest reliability (reproducibility) demonstrated strong stability (intra‐class correlation coefficients >0.7 for the total NBSS). No ceiling or floor effects were present. Conclusions The Polish NBSS demonstrated good measurement properties for a large cohort of patients with NLUTD. It is a suitable tool to assess NLUTD symptoms, consequences and quality of life. The Polish NBSS will support routine clinical practice of all types of physicians in Poland who care for patients with NLUTD.

show abstract

“…Poland is considered to be a high-risk area for MS, with a crude prevalence rate of 108.7/100,000 for the Podlaskie Voivodeship (similar in other regions of Poland) [5]. The MS patient group chosen for the study was statistically representative of the population of patients with relapsing-remitting MS in the Podlaskie Voivodeship.…”

Section: Discussionmentioning

confidence: 99%

Herpesviridae Seropositivity in Patients with Multiple Sclerosis: First Polish Study

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system that leads to inflammation, demyelination and neurodegeneration. Viral aetiology has been suspected to be an MS trigger for a long time, and herpesviruses (HSs) are among the potential pathogens involved. Objectives: The present investigation aims to detect the presence of antibodies against the herpes simplex virus (HSV), varicella-zoster virus, Epstein-Barr virus (EBV), human cytomegalovirus (CMV) and human herpesvirus 6 (HHV6) in the serum of MS patients and control individuals in north-eastern Poland. Method: Plasma was collected from 141 MS patients and 44 blood donors who served as the control group. These individuals were assessed for the presence of antibodies using an enzyme-linked immunosorbent assay. Results: The statistical analysis showed a higher probability of EBV (p = 0.037, OR 4.359) and HHV6 (p = 0.020, OR 3.343) antibody presence in patients with MS compared to that in the control group. In the MS patient group, the prevalence of CMV IgG antibodies was significantly higher in females (p = 0.025). Patients who tested positive for anti-EBV IgG were diagnosed 7.9 years earlier than patients who tested negative for anti-EBV IgG (p = 0.048). Conclusions: The study showed that MS patients in north-eastern Poland were more likely to be seropositive for EBV and HHV6 than healthy individuals. Further work should be undertaken in other regions of Poland and other European countries with particular attention paid to testing seropositivity in all HSs, particularly in the MS patient population, to evaluate the impact of HSs on MS patients in different environments.

show abstract

Prevalence of multiple sclerosis in Poland

Cited by 37 publications

References 20 publications

Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland

Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland

Neurogenic bladder symptom score: Polish translation, adaptation and validation of urinary disorder‐specific instrument for patients with neurogenic lower urinary tract dysfunction

Herpesviridae Seropositivity in Patients with Multiple Sclerosis: First Polish Study

Contact Info

Product

Resources

About